Cnopf'sche Kinderklinik
- Address
- St.-Johannis-Mühlgasse 19, 90419 Nuremberg, Germany
Hemic and Lymphatic Diseases
The pediatric oncology and hematology department at Cnopf'sche Kinderklinik focuses on blood‑related cancers in children, especially lymphoblastic lymphoma. It also studies myeloid leukemia in children with Down syndrome to improve survival outcomes. Research aims to enhance event‑free survival and reduce relapse through refined chemotherapy regimens. The team evaluates alternative steroids to lower central nervous system relapse rates.
- Optimizing induction therapy to lower central nervous system relapse
- Evaluating dexamethasone versus prednisone in treatment protocols
- Assessing intensified PEG‑asparaginase schedules
- Measuring five‑year event‑free survival in Down syndrome‑associated leukemia
The site collaborates internationally to deliver therapies that match historic benchmarks while minimizing toxicity. Families in Nürnberg benefit from access to cutting‑edge trials.
Neoplasms
The clinic advances care for a broad range of pediatric neoplasms, including both solid tumors and leukemias. A key study tests the novel agent CPX‑351 in children with Down syndrome‑associated leukemia. The goal is to raise cure rates and long‑term survival. International cooperative protocols guide treatment of lymphoblastic lymphoma across Europe.
- Phase III evaluation of CPX‑351 in pediatric myeloid leukemia
- International cooperative protocols for lymphoblastic lymphoma
- Long‑term follow‑up of event‑free survival outcomes
- Integrating targeted agents into standard chemotherapy
By uniting clinical expertise with cutting‑edge research, the department strives to set new standards in pediatric cancer treatment. Patients benefit from access to innovative therapies within a dedicated European research network.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1GPOH gGmbH1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cnopf'sche Kinderklinik
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Dexamethasone Versus Prednisone in Induction Therapy for Pediatric and Adolescent Lymphoblastic Lymphoma: A Randomized Controlled Trial | Universitaetsklinikum Muenster AöR | Phase III | Recruiting | Aug 2019 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 2 | Unknown | 2019-08-01 | 2024-10-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.